Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
(Biotech Stocks Hitting 52-week highs Jan. 15)
- Adial Pharmaceuticals Inc (NASDAQ:ADIL)
- Avenue Therapeutics Inc (NASDAQ:ATXI)
- SI-Bone Inc (NASDAQ:SIBN)
Down In The Dumps
(Biotech stocks hitting 52-week lows Jan. 15)
- Bio-Path Holdings Inc (NASDAQ:BPTH)(priced 8.59 million common stock offering at 13 cents per share)
- Neuronetics Inc (NASDAQ:STIM)
- Selecta Biosciences Inc (NASDAQ:SELB)
Stock In Focus
Revance to Offer $100M Worth Shares
Revance Therapeutics Inc (NASDAQ:RVNC) said it will sell $100 million shares in an underwritten common stock offering. The company intends to use the net proceeds for working capital and general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The stock fell 4.41 percent to $19.30 in after-hours trading.
ContraVir, Trovagene Adjourn Shareholder Meetings
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) said its 2018 annual stockholders meeting originally scheduled for Jan. 15 stands adjourned due to a lack of quorum on the proposals to be approved,
Separately, TrovaGene Inc (NASDAQ:TROV) announced adjournment of its annual shareholders meetings, scheduled for Jan. 15, to Feb. 12.
"At the meeting, it was deemed that the holders of a sufficient number of Trovagene's outstanding common stock have not yet submitted proxies to indicate how their shares should be voted and additional time was needed to collect the required votes," the company said.
In after-hours trading, ContraVir rose 2.48 percent to 34 cents and Trovagene climbed 2.88 percent to 55 cents.
On The Radar
Adcom Meeting
The Bone, Reproductive and Urologic Drugs Advisory Committee is scheduled to discuss Amgen, Inc. (NASDAQ:AMGN)'s BLA for romosozumab injection for treating osteoporosis in postmenopausal women at high risk of fracture.
Related Link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.